纳武利尤单抗联合近距离放疗与外照射治疗GG5前列腺癌的I期初步结果:安全性、可行性及探索性分析
这项I/II期试验评估纳武利尤单抗联合ADT、高剂量率近距离放疗和外照射在Grade Group 5前列腺癌中的安全性。6例患者中1例出现3级剂量限制性肝酶升高,3例(50%)活检显示早期应答,应答者组织CD8+和FOXP3+/CD4+ T细胞及外周血CD4+效应T细胞增加。
要点
- 纳武利尤单抗联合ADT和HDR近距离放疗总体耐受良好。
- 1例出现3级剂量限制性肝酶升高。
- 50%患者活检显示早期应答并伴免疫细胞浸润增加。
核心结论
- 纳武利尤单抗联合ADT和高剂量率近距离放疗耐受良好,并伴随免疫浸润增加和抗肿瘤活性证据。
研究设计与样本
- I/II期试验,纳入6例Grade Group 5前列腺癌患者,接受ADT、纳武利尤单抗每两周共4周期、两次HDR近距离放疗及外照射放疗。
主要发现
- 1例患者在第二周期纳武利尤单抗后出现3级剂量限制性毒性(丙氨酸氨基转移酶和天冬氨酸氨基转移酶升高)。
- 3例患者(50%)在纳武利尤单抗4周期后及HDR后1个月活检中≥4/6针无残留肿瘤,显示早期应答。
- 早期应答者组织中CD8+和FOXP3+/CD4+ T细胞及外周血CD4+效应T细胞增加。
关键数值与推荐
- 主要终点为安全性和可行性;6例患者中1例出现3级剂量限制性毒性。
- 早期应答定义为纳武利尤单抗4周期后及HDR后1个月活检≥4/6针无残留肿瘤,3例(50%)达到。
临床怎么用
- 对于GG5前列腺癌,纳武利尤单抗联合ADT和HDR近距离放疗可能是一种可行且耐受良好的治疗策略,但需进一步验证。
局限性
- 样本量小(6例),为I期安全性导入部分,观察期短(至少3个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To determine whether combining brachytherapy with immunotherapy is safe in prostate cancer (PCa) and provides synergistic effects, we performed a Phase I/II trial on the feasibility, safety, and benefit of concurrent delivery of anti-PD-1 (nivolumab) with high-dose-rate (HDR) brachytherapy and androgen deprivation therapy (ADT) in patients with Grade Group 5 (GG5) PCa. METHODS: Eligible patients were aged 18 years or older with diagnosis of GG5 PCa. Patients received ADT, nivolumab every two weeks for four cycles, with two cycles prior to first HDR, and two more cycles prior to second HDR, followed by external beam radiotherapy. The primary endpoint was to determine safety and feasibility. This Phase I/II trial is registered with ClinicalTrials.gov (NCT03543189). RESULTS: Between September 2018 and June 2019, six patients were enrolled for the Phase I safety lead-in with a minimum observation period of 3 months after nivolumab administration. Overall, nivolumab was well tolerated in combination with ADT and HDR treatment. One patient experienced a grade 3 dose-limiting toxicity (elevated Alanine aminotransferase and Aspartate aminotransferase) after the second cycle of nivolumab. Three patients (50%) demonstrated early response with no residual tumor detected in ≥4 of 6 cores on biopsy post-nivolumab (4 cycles) and 1-month post-HDR. Increase in CD8+ and FOXP3+/CD4+ T cells in tissues, and CD4+ effector T cells in peripheral blood were observed in early responders. CONCLUSION: Combination of nivolumab with ADT and HDR is well tolerated and associated with evidence of increased immune infiltration and antitumor activity.
引用
- Yuan Z, Fernandez D, Dhillon J, et al. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer Prostatic Dis. 2020. PMID: 32651467. doi:10.1038/s41391-020-0254-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。